早期宫颈癌前哨淋巴结活检的长期肿瘤学安全性:SENTICOL I和II队列的事后分析
本研究基于SENTICOL I和II两项前瞻性多中心试验的辅助分析,比较早期宫颈癌双侧前哨淋巴结阴性患者仅行前哨淋巴结活检(SLNB)与盆腔淋巴结清扫(PL)的肿瘤学结局。结果显示两组无病生存率和疾病特异性生存率相似,SLNB与PL相比未显著增加复发风险,但生存非劣效性需前瞻性试验证实。
要点
- 双侧SLN阴性早期宫颈癌患者省略盆腔淋巴结清扫未显著增加复发风险。
- SLNB组与PL组的DFS和DSS差异无统计学意义。
- 仅Sedlis病理风险分级是DFS和DSS的独立预测因素。
核心结论
- 在双侧SLN阴性早期宫颈癌患者中,省略全盆腔淋巴结清扫似乎不增加复发风险。
- 生存非劣效性尚需前瞻性试验确认。
研究设计与样本
- 对SENTICOL I和II两项前瞻性多中心试验的辅助分析。
- 纳入早期宫颈癌(IA-IIA FIGO分期)、双侧SLN检出、超分期后SLN阴性且最终病理非SLN阴性的患者。
- 2005年1月至2012年7月共分析259例淋巴结阴性患者:SLNB组87例,PL组172例。
- 中位随访47个月(范围4-127个月)。
主要发现
- 随访期间21例(8.1%)复发,包括4例(1.9%)淋巴结复发,9例(3.5%)死于宫颈癌。
- SLNB组与PL组的DFS分别为85.1%和80.4%(p=0.24),DSS分别为90.8%和97.2%(p=0.22)。
- Cox多因素分析显示SLNB与PL相比DFS无显著关联(HR=1.78,95%CI 0.71-4.46,p=0.22),DSS亦无显著关联(HR=3.02,95%CI 0.69-13.18,p=0.14)。
- 仅Sedlis标准病理风险分级是DFS和DSS的独立预测因素。
关键数值与推荐
- DFS:SLNB组85.1% vs PL组80.4%,p=0.24。
- DSS:SLNB组90.8% vs PL组97.2%,p=0.22。
- DFS的HR=1.78(95%CI 0.71-4.46,p=0.22);DSS的HR=3.02(95%CI 0.69-13.18,p=0.14)。
临床怎么用
- 对于早期宫颈癌且双侧SLN超分期阴性的患者,可考虑省略全盆腔淋巴结清扫。
- 应依据Sedlis标准评估病理风险以指导预后判断。
局限性
- 为事后辅助分析,非随机对照设计。
- 样本量有限,随访时间中等。
- 生存非劣效性需前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare oncologic outcomes of patients with early-stage cervical cancer and negative nodes who underwent sentinel lymph node biopsy alone (SLNB) versus pelvic lymphadenectomy (PL). METHODS: An ancillary analysis of two prospective multicentric trials on SLN biopsy for cervical cancer (SENTICOL I and II) was conducted. Only patients with early-stage cervical cancer (IA to IIA FIGO stage), bilateral detection of SLN, negative SLN after ultrastaging and negative non-SLN after final pathologic examination were included. Risk-factors of recurrence and disease-specific mortality were determined by Cox proportional hazard models. RESULTS: Between January 2005 and July 2012, 259 node-negative patients were analyzed: 87 in the SLNB group and 172 in the PL group. The median follow-up was 47 months [4-127]. During the follow-up, 21 patients (8.1%) experienced recurrences, including 4 nodal recurrences (1.9%), and 9 patients (3.5%) died of cervical cancer. Disease-free survival (DFS) and disease-specific survival (DSS) were similar between SLNB and PL groups, 85.1% vs. 80.4%, p = 0.24 and 90.8% vs. 97.2%, p = 0.22 respectively. By Cox multivariate analysis, SLNB compared to PL was not associated with DFS (HR = 1.78, 95%CI = [0.71-4.46], p = 0.22) neither with DSS (HR = 3.02, 95%CI = [0.69-13.18], p = 0.14). Only pathologic risk level according to the Sedlis criteria was an independent predictor of DFS and DSS. CONCLUSIONS: Omitting full pelvic lymphadenectomy for patients with bilateral negative SLN does not seem to be associated with an increased risk of recurrence in this series. Survival non-inferiority needs to be confirmed by prospective trials.
引用
- Balaya V, Guani B, Morice P, et al. Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts. Gynecol Oncol. 2021. PMID: 34696894. doi:10.1016/j.ygyno.2021.10.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。